As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ: BMRN) and its peers.
Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth.
The 10 therapeutics stocks we track reported a satisfactory Q4. As a group, revenues beat analysts’ consensus estimates by 2.6%.
While some therapeutics stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 1.2% since the latest earnings results.
Best Q4: BioMarin Pharmaceutical (NASDAQ: BMRN)
Pioneering treatments for conditions that often had no previous therapeutic options, BioMarin Pharmaceutical (NASDAQ: BMRN) develops and commercializes therapies that address the root causes of rare genetic disorders, particularly those affecting children.
BioMarin Pharmaceutical reported revenues of $747.3 million, up 15.6% year on year. This print exceeded analysts’ expectations by 4.8%. Overall, it was a stunning quarter for the company with an impressive beat of analysts’ EPS estimates.
"Our operational transformation and strong financial execution in 2024 is the first step in BioMarin's ambitious multiyear growth plan," said Alexander Hardy, President and Chief Executive Officer of BioMarin.
BioMarin Pharmaceutical pulled off the highest full-year guidance raise of the whole group. The stock is up 7.5% since reporting and currently trades at $70.61.
Is now the time to buy BioMarin Pharmaceutical? Access our full analysis of the earnings results here, it’s free.
Gilead Sciences (NASDAQ: GILD)
From its groundbreaking work in developing the first single-tablet regimens for HIV treatment, Gilead Sciences (NASDAQ: GILD) develops and markets innovative medicines for life-threatening diseases including HIV, viral hepatitis, COVID-19, and cancer.
Gilead Sciences reported revenues of $7.57 billion, up 6.4% year on year, outperforming analysts’ expectations by 6.3%. The business had a very strong quarter with an impressive beat of analysts’ full-year EPS guidance estimates.
Gilead Sciences delivered the biggest analyst estimates beat among its peers. The market seems happy with the results as the stock is up 9.8% since reporting. It currently trades at $105.58.
Is now the time to buy Gilead Sciences? Access our full analysis of the earnings results here, it’s free.
Slowest Q4: Moderna (NASDAQ: MRNA)
Rising to global prominence during the COVID-19 pandemic with one of the first effective vaccines, Moderna (NASDAQ: MRNA) develops messenger RNA (mRNA) medicines that direct the body's cells to produce proteins with therapeutic or preventive benefits for various diseases.
Moderna reported revenues of $966 million, down 65.6% year on year, in line with analysts’ expectations. It was a slower quarter as it posted full-year revenue guidance missing analysts’ expectations.
Moderna delivered the slowest revenue growth and weakest full-year guidance update in the group. Interestingly, the stock is up 2% since the results and currently trades at $32.60.
Read our full analysis of Moderna’s results here.
Sarepta Therapeutics (NASDAQ: SRPT)
Pioneering treatments for a devastating childhood muscle-wasting disease that primarily affects boys, Sarepta Therapeutics (NASDAQ: SRPT) develops and commercializes RNA-targeted therapies and gene therapies for rare genetic disorders, primarily Duchenne muscular dystrophy.
Sarepta Therapeutics reported revenues of $658.4 million, up 65.9% year on year. This number surpassed analysts’ expectations by 4.3%. Aside from that, it was a mixed quarter as it logged a significant miss of analysts’ EPS estimates.
Sarepta Therapeutics achieved the fastest revenue growth among its peers. The stock is down 30.9% since reporting and currently trades at $74.
Read our full, actionable report on Sarepta Therapeutics here, it’s free.
Amgen (NASDAQ: AMGN)
Founded in 1980 during the early days of the biotechnology revolution, Amgen (NASDAQ: AMGN) is a biotechnology company that discovers, develops, and manufactures innovative medicines to treat serious illnesses like cancer, osteoporosis, and autoimmune diseases.
Amgen reported revenues of $9.09 billion, up 10.9% year on year. This print beat analysts’ expectations by 2.6%. More broadly, it was a satisfactory quarter as it also produced full-year revenue guidance slightly topping analysts’ expectations.
The stock is up 8.9% since reporting and currently trades at $314.67.
Read our full, actionable report on Amgen here, it’s free.
Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Quality Compounder Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
Join Paid Stock Investor Research
Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here.
